Evidence map›Paper›PMID 34325798›Full record

ArticleMethods in enzymology2021

Incorporation of proline analogs into recombinant proteins expressed in Escherichia coli.

Stephanie L Breunig, David A Tirrell

Abstract read
In one paragraph

Article in Methods in enzymology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Stephanie L BreunigDivision of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, CA, United States.
David A TirrellDivision of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, CA, United States. Electronic address: tirrell@caltech.edu.

Funding

Non-canonical amino acid mutagenesis in the engineering of insulin biophysicsR01GM134013 · NIGMS · CALIFORNIA INSTITUTE OF TECHNOLOGY · PI TIRRELL, DAVID A · 2019 to 2021
$913k
NIGMS NIH HHS R01 GM134013
6 · The paper itself

Abstract

Proline residues are unique in the extent to which they constrain the conformational space available to the protein backbone. Because the conformational preferences of proline cannot be recapitulated by any of the other proteinogenic amino acids, standard mutagenesis approaches that seek to introduce new chemical functionality at proline positions unavoidably perturb backbone flexibility. Here, we detail the incorporation of proline analogs into recombinant proteins in Escherichia coli via a residue-specific mutagenesis strategy. This approach results in global replacement of proline residues with high yields of the recombinant protein of interest, minimal genetic manipulation, and maintenance of backbone conformational constraints.

Indexed as

Escherichia coliProlineAmino AcidsMolecular ConformationProtein ConformationRecombinant ProteinsAmino AcidsProlineRecombinant ProteinsEscherichia coliNon-canonical amino acidProline analogProtein conformationRecombinant proteinResidue-specific mutagenesis

Identifiers

PMID34325798
PMCPMC9009304

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.